Black Diamond Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
07/08/2025 18:13
Black Diamond Therapeutics Inc BDTX.OQ reported a quarterly adjusted loss of 19 cents per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -36 cents. The mean expectation of four analysts for the quarter was for a loss of 25 cents per share. Wall Street expected results to range from -25 cents to -24 cents per share. Reported revenue was zero; analysts expected zero. Black Diamond Therapeutics Inc's reported EPS for the quarter was a loss of 19 cents. The company reported a quarterly loss of $10.56 million. Black Diamond Therapeutics Inc shares had risen by 8.5% this quarter and gained 25.7% so far this year. FORECAST CHANGES The mean earnings estimate of analysts had risen by about 1% in the last three months. In the last 30 days, there have been no earnings estimate revisions by analysts covering the company. RECOMMENDATIONS The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy" Wall Street's median 12-month price target for Black Diamond Therapeutics Inc is $11.00, about 75.5% above its last closing price of $2.69 This summary was machine generated from LSEG data August 7 at 05:12 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
| QUARTER ENDING | ESTIMATE | ACTUAL | BEAT, MET, MISSED |
| Jun. 30 2025 | -0.25 | -0.19 | Beat |
| Mar. 31 2025 | 0.02 | 0.98 | Beat |
| Dec. 31 2024 | -0.31 | -0.28 | Beat |
| Sep. 30 2024 | -0.37 | -0.28 | Beat |